Promising cancer drug aces human clinical trials

A new cancer drug known as BLU-667 has moved through phase I human trials, and the results are promising. Taken orally, the drug targets what are known as RET-driven cancers, including types of thyroid and lung cancers, which are normally hard to treat…
Continue Reading Promising cancer drug aces human clinical trials

Category: Medical






University of Texas

Related Articles:

Lab-made liver tissue may be used for drug screening

Non-invasive treatment produces 98 percent prostate cancer cure rate

Avocado seed husks jam-packed with medicinal compounds

Reactivation of a single gene turns colorectal cancer cells back into normal tissue

Developing countries to benefit from MPP and Gilead HIV drug licensing agreement

Scientists identify novel drug mechanism that fights brain cancer

The message will be closed after 20 s